Fig. 1: AML xenografts are susceptible to transient LNP/miR-193b treatment in vitro. | Leukemia

Fig. 1: AML xenografts are susceptible to transient LNP/miR-193b treatment in vitro.

From: Preclinical testing of miRNA-193b-3p mimic in acute myeloid leukemias

Fig. 1

A The absolute number of human AML PDX cells after treatment with single dose of 4 µg/ml LNPs. B Percentage of apoptotic cells (Annexin V+) on day 2 post treatment. A, B Data are represented as the mean ± standard deviation of three independent biological replicates (two-way ANOVA). C Absolute number of CFUs in methylcellulose-based colony-forming assays of LNPs-treated AML PDXs. Data are shown as the mean ± standard deviation of four plates from two biological replicates (two-way ANOVA).

Back to article page